Introduction
Recently, multifunctional nanocomposites that combine diagnostic and therapeutic functions have drawn an increasing concern. Ideally, in addition to safety and nontoxicity, these multifunctional nanocomposites should also have high drug-loading efficiencies and real-time imaging capabilities. More importantly, these nanocomposites should lead to lower toxicity to normal cells. 1, 2 Magnetic Fe 3 O 4 nanoparticles (NPs) is one of the inorganic-based nanomaterials approved for clinical use, which showed great biocompatibility and has attracted significant attention due to their unique characteristics such as magnetic resonance imaging (MRI) response to an external magnetic field. 3, 4 Later, many biocompatible polymers, including chitosan, polyethylene glycol (PEG), and dextran, have been used to be coated in Fe 3 O 4 NPs in order to further improve the properties of Fe 3 O 4 NPs. [5] [6] [7] As a major pigment of naturally occurring melanin, 8 polydopamine (PDA) is highly biocompatible and biodegradable. 9 Due to its nature, PDA has been widely used, to be coated in NPs, for various biomedical applications. Meanwhile, by dispersing the as-prepared cores in an alkaline dopamine solution, PDA could spontaneously form a conformal layer through in situ polymerization. 10 In addition, PDA has rich functional groups such as amino and catechol, which can facilitate the further functionalization of PDA-based NPs with biomolecules and can improve the stability and functionality of NPs. 9 Recent evidence has demonstrated that PDA-coated gold nanoshells could be stable within the cells of liver and spleen for at least 6 weeks. 10 Photothermal therapy (PTT) is a new noninvasive cancer treatment technique, which is mediated by inorganic NPs responsive to near-infrared (NIR) light and could convert light energy into thermal energy. 11 As a new PTT agent, in addition to excellent biocompatibility in vitro and in vivo, PDA also had the strong NIR absorbance and high photothermal conversion efficiency (up to 40%). 12, 13 This study fabricated doxorubicin (DOX)-coated Fe 3 O 4 @ PDA NPs that could be simultaneously used for NIRresponse PTT, chemotherapy, and MRI. Although there were reports about the synthesis and applications of Fe 3 O 4 @ PDA NPs, 14, 15 to the best of our knowledge, the combination of PTT with chemotherapy (DOX) for the applications of antibody-targeted Fe 3 O 4 @PDA NPs has not been explored until now. Several reports showed that the tumors could not be completely eradicated by PTT alone due to the absorption and scattering of the NIR light by the biological tissues. 16, 17 Then, integration of an efficient chemotherapy drug with PTT (termed chemo-photothermal therapy) is promising for enhanced and optimized antitumor efficacy. [18] [19] [20] DOX, as an aromatic chemotherapy drug, can be effectively loaded onto the PDA shell via π-π stacking. Using DOX-loaded NPs as the model system, it was confirmed that the intracellular uptake of Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs and the release of DOX from Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs localized inside the cells could be stimulated by NIR laser irradiation due to mild photothermal heating. The combined chemo-photothermal therapy achieved excellent synergistic therapeutic efficacy both in vitro and in vivo. The Fe 3 O 4 @PDA-PEG-EGFR NPs could further be utilized as the T 2 contrast agent in MRI to track tumor development. The results of the present study promised the use of Fe 3 O 4 @PDA core-shell NPs for combined antitumor chemo-photothermal therapy and MRI.
Materials and methods Materials
Iron acetylacetonate (Fe (acac) 3 ), 1,2-hexadecanediol, benzyl ether, oleyamine (OLA), oleic acid (OA), sodium dodecyl sulfate (SDS), dopamine hydrochloride (DP), 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC), and N-hydroxysuccinimide (NHS) were purchased from Millipore-Sigma (Darmstadt, Germany). Dulbecco's Modified Eagle's Medium (DMEM) with high glucose and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). NH 2 -PEG-COOH (molecular weight =2,000 Da) was purchased from Seebio Biological (Shanghai, China). DOX hydrochloride was purchased from Sangon Ltd. (Shanghai, China). Anti-EGFR antibody was obtained from Ruiying Biological (Suzhou, China). Other reagents (analytical grade) were purchased from Beijing Chemical Reagents Company (Beijing, China) unless otherwise stated.
cells and animals
The DLD-1 human colon cancer cell line was purchased from American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM supplemented with 10% FBS in a humidified 5% CO 2 atmosphere at 37°C.
Female BALB/c nude mice (5-6 weeks old) were purchased from Vital River Company (Beijing, China) and were maintained under specific pathogen-free conditions. The animals were treated according to the ethical guidelines of Jilin University after obtaining approval from the Animal Welfare and Research Ethics Committee of Jilin University. The animal experiments were carried out following the internationally accepted animal care guidelines (EEC Directive of 1986; 86/609/EEC).
Preparation of Fe 3 O 4 @PDa-Peg-egFr NPs
Fe 3 O 4 @PDA-PEG-EGFR NPs were prepared as shown in Figure 1 
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Immunofluorescence DLD-1 cells were fixed in 4% paraformaldehyde for 15 min and permeabilized with 0.1% Triton X-100 in PBS for 30 min. Then, the cells were washed and blocked with 5% bovine serum albumin for 30 min. Cells were incubated with the primary EGFR antibodies (1:100; Ruiying Biological) overnight at 4°C. Then, the cells were washed and incubated with goat anti-mouse immunoglobulin G conjugated with fluorescein isothiocyanate for 1 h at room temperature. 4,6-Diamidino-2-phenylindole (DAPI; 1:10,000; Beyotime, Shanghai, China) was used for nucleus staining. Images were detected by using a fluorescence microscope (IX5-RFACA; Olympus Corporation, Tokyo, Japan).
characterization of Fe 3 O 4 @PDa-PegegFr NPs
The morphology of NPs was analyzed by using transmission electron microscope (TEM; Hitachi H-800 Hitachi, Tokyo, Japan). The size and its distribution of NPs were determined by dynamic light scattering (DLS) (Malvern Zetasizer Nano Instrument; Malvern Instruments, Malvern, UK). The zeta potentials of the as-prepared NPs were measured by using a Zetasizer Nano ZS (Malvern Instruments). The Fourier transform-infrared (FT-IR) spectroscopy of NPs was performed by using a Bruker Vertex 70 FT-IR spectrometer (Bruker, Karlsruhe, Germany) in the range from 400 to 4,000 cm 
ph-and photothermal-sensitive DOX release
Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs were suspended in PBS at different pH, sealed in a dialysis bag (molecular weight cutoff =8,000 Da), and then were immersed into PBS solution at pH 5.0 or 7.4 at 37°C with moderate shaking for different periods of time. At desired time intervals, DOX in the release medium was collected, then the concentrations were determined by UV-vis spectrometry. The release medium was replaced with an equal volume of fresh PBS. The 808 nm NIR laser-triggered DOX release experiments were conducted following the same procedure as mentioned earlier. At predetermined time intervals, the samples were irradiated with an 808 nm NIR laser (0.6 W/cm 2 ) for 6 min. DOX in the dialysis buffer released from NPs was collected before and after 808 nm NIR laser irradiation.
In vitro photothermal experiments
A series of Fe 3 O 4 @PDA-PEG-EGFR NPs aqueous solutions with different concentrations (0, 25, 50, 75, 100, and 150 µg/ mL) were irradiated with an 808 nm NIR laser (0.6 W/cm 2 ) for 6 min. The solution temperature was measured every 1 min by a thermometer with a thermocouple probe submerged in the solution. To detect the thermal stability of Fe 3 O 4 @PDA-PEG-EGFR NPs, the samples were irradiated for 6 min every time, followed by natural cooling of temperature to room temperature for five cycles, and the temperature was recorded every 1 min. were incubated with Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs (equal to DOX 5 µg/mL) for 6, 12, 24, and 36 h at 37.0°C. At predetermined time points after incubation, the cells were fixed with a 4% paraformaldehyde, and the cellular nuclei were stained with DAPI (1:10,000; Beyotime). The results were characterized by using a fluorescence microscope. In a separate experiment, DLD-1 cells were irradiated with the 808 nm NIR laser (0.6 W/cm 2 ) for 6 min after incubation with Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs (equal to DOX 5 µg/mL) dispersions for 12 h. Then, the cells were treated in accordance with the aforementioned method and characterized by using a fluorescence microscope. ) for 6 min and were incubated at 37°C for another 24 h. Later, 10 µL of CCK-8 was added to each well. After incubation for 2 h, the absorbance of each well was read on a Microplate Reader (ELx-800; BioTek Instruments, Winooski, VT, USA) at 450 nm. The relative cell viability (%) related to the control wells containing cell-culture medium was calculated by using the following equation: Cell viability (%) = A Test sample /A Control × 100%, where A Test sample and A Control were the absorbance of the test sample and the control, respectively.
In vitro MrI of phantom

In vivo MrI
To develop the tumor model, DLD-1 cells (100 µL, 1×10 7 / mL) suspended in PBS were inoculated subcutaneously into the back of each mouse. For in vivo MRI, desired amounts of Fe 3 O 4 @PDA-PEG-EGFR NPs in PBS solutions (100 µL) were injected intravenously into the mouse through the tail vein. In vivo MRI was performed at predetermined time points after injection. The T 2 -weighted MRI parameters were shown as follows: TR, 3,980.0 ms; TE, 99.0 ms; field of view, 400.0 mm; and slice thickness, 6.0 mm.
In vivo chemo-photothermal therapy
For chemo-photothermal therapy, when the tumors grew to 5-6 mm in diameter, the mice were randomly divided into histological analysis BALB/c mice from the treatment group were killed, and the tumor tissues and other major organs including heart, liver, spleen, lung, and kidney were collected for analysis after various treatments. The frozen tissue slides were further stained with hematoxylin and eosin following the standard protocol and examined using a fluorescence microscope.
statistical analysis
All values are expressed as the mean ± SD and analyzed by using Student's t-test. P-values ,0.05 were considered statistically significant. (Figure 2A) , whereas the average hydrodynamic diameter measured by DLS was ∼91.2±31.1 nm ( Figure 2B ). Absorption bands, 3,421 cm −1 (N-H stretching) and 1,524 cm −1 (N-H bending) in the FT-IR spectrum of Fe 3 O 4 @PDA (as shown in Figure 2C) Figure 2D, Because of the presence of magnetic iron oxide core, the Fe 3 O 4 @PDA-PEG-EGFR NPs displayed strong magnetic property. When placed beside a magnet, the Fe 3 O 4 @ PDA-PEG-EGFR NPs in aqueous solution was attracted by a magnet, which was almost unchanged without a magnet ( Figure 3A) . The strong super paramagnetism of Fe 3 O 4 @ PDA-PEG-EGFR NPs was further revealed by the fielddependent magnetization hysteresis loop ( Figure 3B ). Fe 3 O 4 NPs have been widely used as a T 2 -contrast agent for MRI. 24, 25 As shown in Figure 3C and D, the T 2 -weighted MR images exhibited increasingly darkening effect with the increase of Fe 3 O 4 @PDA-PEG-EGFR NPs concentration. This result suggested that Fe 3 O 4 @PDA-PEG-EGFR NPs could be used as a T 2 -weighted MRI contrast agent.
Results and discussion
Photothermal properties of Fe 3 O 4 @ PDa-Peg-egFr NPs
The photothermal conversion capability of Fe 3 O 4 @PDA-PEG-EGFR NPs was evaluated by irradiating Fe 3 O 4 @ PDA-PEG-EGFR aqueous solution with an 808 nm NIR laser at 0.6 W/cm 2 . As shown in Figure 4A , the temperature strikingly rised with increasing concentration of Fe 3 O 4 @ PDA-PEG-EGFR NPs, following a time-and concentrationdependent manner. In particular, at an Fe 3 O 4 @PDA-PEG-EGFR NPs concentration of 150 µg/mL, the solution temperature could reach 50°C within 6 min irradiation, which is the temperature required to kill cancer cells. 26 The thermal stability of 
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Mu et al Figure 5B , within 36 h, ∼25% of DOX was released from the Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs at pH 5.0 compared with 6% of DOX release at pH 7.4. The amount of DOX released from Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs at pH 5.0 was approximately fourfold higher than that at pH 7.4. The protonation of the amino group in the DOX molecule gave DOX a positive charge and thus enhanced the hydrophilicity to trigger drug release at a lower pH.
As shown in
To investigate the photothermal influence on DOX release, Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs suspended in PBS at pH 5.0 or 7.4 were irradiated under an 808 nm NIR laser (0.6 W/ cm 2 , 6 min). As shown in Figure 5C , a significant thermotriggered burst release of DOX from Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs was observed at pH 5.0. In comparison, only limited DOX was released at pH 7.4 under the same condition. The pH-dependent NIR-triggered drug release processes enabled regulation of intracellular drug release and minimizing of the side effects of chemotherapy drugs.
cellular uptake of Fe 3 O 4 @PDa-PegegFr-DOX NPs
The cellular uptake and internalization of Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs for the intracellular delivery of DOX were investigated by using DLD-1 human colon cancer cells. First, the level of EGFR expression on the surface of DLD-1 cells was detected by immunofluorescence ( Figure 6A ). The DLD-1 cells were incubated with Fe 3 O 4 @ PDA-PEG-EGFR-DOX NPs for 6, 12, 24, and 36 h. With incubation time increasing from 6 to 36 h, the red fluorescence of DOX was gradually distributed in the cytoplasm and in the nuclei of the Fe 3 O 4 @PDA-PEG-EGFR-DOX NP-treated cells ( Figure 6B ). This result indicated that DOX molecules were released from Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs taken up by DLD-1 cells. In addition, the DOX released from Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs showed slow nuclear clustering because DOX was first released in the cytoplasm, followed by entering into the nucleus. The cellular internalization of Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs was consistent with other reported drug releasing systems. 7, 27 According to the previous studies, the mild photothermal heating caused by the NPs could not only trigger more release of DOX but also increase the cellular internalization of the NPs by promoting cellular metabolism and membrane permeability. [28] [29] [30] [31] In order to further confirm whether the enhanced cell uptake of NPs could be triggered by laser irradiation, DLD-1 cells were incubated with 
chemo-photothermal therapy
Because of the prominent antitumor effect in vitro, the inhibiting tumor effect of Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs was evaluated in vivo. The mice were divided into eight randomized groups and were first treated through intravenous injection of different materials. After treatment, the tumor sizes in different groups of mice were measured every 2 days for a period of 14 days. As shown in Figure 9A and B, tumors in control groups, including PBS injection with or without laser irradiation, as well as Fe 3 O 4 @PDA-PEG injection without laser irradiation, all showed obvious growth. The growth of tumors was slightly increased by Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs without laser irradiation, which is consistent with the previous reports that DOX at such a low dose could not effectively suppress tumor growth. 32 Importantly, more obvious tumor inhibiting effect was achieved from the group with Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs injection and NIR laser irradiation during the 14 days. These in vivo results strongly demonstrated that Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs were more efficient than monotherapy alone for ablation of tumors.
The potential toxicity of the NPs had been a major drawback for practical applications in vivo. In this experiment, it was found that mice in all test groups, especially for groups treated with 
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Mu et al NPs and NIR laser irradiation, behaved normally without a significant decrease in body weight (data not shown). The maintained body weight demonstrated that there was no noticeable toxicity of the prepared NPs in vivo. In addition, histological analysis of the major organs showed that there was no obvious tissue damage after 30 days of chemophotothermal therapy, further confirming the low toxicity of the NPs in vivo ( Figure 9C ).
Conclusion
In summary, the multifunctional Fe 3 O 4 @PDA-PEG-EGFR-DOX NPs capable of simultaneous chemo-photothermal therapy and MRI have been successfully designed and synthesized. DOX could be physically adsorbed on Precision medicine is altering the traditional treatment methods for patients with cancer. Therefore, EGFR antibodytargeted Fe 3 O 4 @PDA-PEG-EGFR-DOX theranostic NPs are a promising receptor-targeted drug delivery system for the individual treatment of EGFR-overexpressed colon cancer.
